Dashboard
$GCTKAug 6, 2026, 12:15 PMAI processed

GCTK raises $5.5M — $2M equity at $0.75/unit plus $3.5M convertible debt; E.F. Hutton advised

AI Summary

Glucotrack (GCTK) completed a $5.5M financing for its Lokahi Therapeutics subsidiary consisting of $2.0M in equity priced at $0.75 per unit and a $3.5M follow-on in convertible debt, with E.F. Hutton acting as exclusive financial advisor. The deal brings fresh capital and institutional participation to support advancement of the company’s therapeutic programs, while adding convertible debt that could convert into equity and impact capitalization.

Positives

  • $5.5M total financing secured
  • $2.0M equity tranche priced at $0.75 per unit
  • $3.5M follow-on provided as convertible debt with institutional investor participation

Negatives

  • Convertible debt may convert into equity and dilute existing shareholders
  • Article does not disclose conversion terms or other debt/equity specifics
  • Use of proceeds not detailed beyond general support for therapeutic advancement